



GENMAB TO PRESENT DATA FROM MULTIPLE STUDIES AT ASH

Summary: Six abstracts have been accepted for presentation at the ASH meeting December 5-8, 2009

Copenhagen, Denmark; November 10, 2009 – Genmab A/S (OMX: GEN) announced today that six abstracts have been accepted for presentation at the 51st American Society of Hematology Annual Meeting and Exposition (ASH) December 5-8, 2009. All abstracts are available on the ASH website at www.hematology.org.

ASH Sessions

Oral Presentation December 7 at 7:30 AM EST – Ofatumumab Combined with Fludarabine and Cyclophosphamide (O-FC) Shows High Activity in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL): Results From a Randomized, Multicenter, International, Two-Dose, Parallel Group, Phase II Trial

Oral Presentation December 7 at 3:00 PM EST – Daratumumab, a Novel Potent Human Anti-CD38 Monoclonal Antibody, Induces Significant Killing of Human Multiple Myeloma Cells: Therapeutic Implication

Oral Presentation December 8 at 8:30AM EST – Evaluation of Ofatumumab, a Novel Human CD20 Monoclonal Antibody, as Single Agent Therapy in Rituximab-Refractory Follicular Lymphoma

Poster Session: CLL – Therapy, Excluding Transplantation II, December 7 between 6:00PM – 8:00 PM EST, Poster III-182 - Correlation Between Serum Ofatumumab Concentrations, Baseline Patient Characteristics and Clinical Outcomes in Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ofatumumab

Poster Session: Molecular Pharmacology, Drug Resistance I, December 5 between 5:30PM – 7:30 PM EST, Poster I-747 - Ofatumumab, a human mAb targeting a membrane-proximal small-loop epitope on CD20, induces potent NK cell-mediated ADCC

Poster - The humanized Multiple Myeloma mouse model: opportunities for studying the pathogenesis of MM in its natural environment

About Ofatumumab

Ofatumumab is a monoclonal antibody that causes the body's immune response to fight against normal and cancerous B-cells. Ofatumumab attaches to the small and large loop epitopes - on a

GENMAB TO PRESENT DATA FROM MULTIPLE STUDIES AT ASH

molecule called CD20, which is found on the surface of B-cells, the type of cell which becomes cancerous in CLL.

Ofatumumab is being developed under a co-development and commercialization agreement between Genmab and GlaxoSmithKline. Ofatumumab is approved in the US for treatment of chronic lymphocytic leukemia that is refractory to fludarabine and alemtuzumab. Ofatumumab is not approved in any other country or for any other indication.

About Daratumumab

Daratumumab (HuMax-CD38™) is a fully human IgG1,κ antibody in development to treat multiple myeloma (MM). Daratumumab targets the CD38 molecule which is very highly expressed on the surface of multiple myeloma cells. The antibody was selected from a large panel of antibodies based on its ability to bind to and kill multiple myeloma tumor cells.

About Genmab A/S

Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for the potential treatment of cancer. Genmab's world class discovery and development teams are using cutting-edge technology to create and develop products to address unmet medical needs. Our primary goal is to improve the lives of patients who are in urgent need of new treatment options. For more information on Genmab's products and technology, visit www.genmab.com.

This press release contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the section "Risk Management" in Genmab's Annual Report, which is available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this press release nor to confirm such statements in relation to actual results, unless required by law.

Genmab®; the Y-shaped Genmab logo®; HuMax®; HuMax-CD20®; HuMax-EGFr™; HuMax-IL8™; HuMax-TAC™; HuMax-HepC™; HuMax-CD38™; HuMax-CD32b™; HuMax-TF™; HuMax-Her2™; HuMax-VEGF™ and UniBody® are all trademarks of Genmab A/S. Arzerra™ is a trademark of GlaxoSmithKline.

Contact: Helle Husted, Vice President, Investor Relations
T: +45 33 44 77 30; M: +45 25 27 47 13; E: h.husted@genmab.com

###